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353urrently used thrombolytic reperfusion regimens improve
urvival in patients with acute ST-segment elevation myo-
ardial infarction (STEMI) (1). This clinical benefit is
argely dependent on their ability to: 1) achieve timely and
omplete restoration of anterograde epicardial blood flow in
he infarct-related artery (Thrombolysis In Myocardial
nfarction [TIMI] flow grade 3) (2–4); and 2) improve
icrovascular or myocardial tissue level perfusion as deter-
ined by ST-segment resolution, contrast echocardiogra-
hy, or TIMI perfusion grade/“blush score” (5–7). Hence,
he absence of TIMI flow grade 3 and the lack of electro-
ardiographic ST-segment resolution after thrombolysis are
trongly associated with death and poor outcome in patients
ith STEMI (2,3,7,8).
Approximately one-half of STEMI patients fail to
chieve optimal infarct artery patency and/or myocardial
issue perfusion with current thrombolytic regimens (1–3).
ore aggressive antithrombotic regimens modestly increase
atency rates but are associated with more bleeding and no
lear mortality benefit. Therapeutic low-frequency transcu-
aneous ultrasound (TUS) is a potential adjunctive therapy
o thrombolysis that might enhance coronary thrombolysis
ithout increased bleeding (9). In preclinical studies, the
ombination of TUS and thrombolytic agents improves
atency in coronary and peripheral artery thrombosis mod-
ls compared with thrombolysis alone (9–15). Mechanisti-
ally, this enhanced thrombolysis effect has been attributed
o TUS effects on fibrin bundle disaggregation, acoustic
avitation, microstreaming, increased clot permeability to
hrombolytic agents, and coronary vasodilatation (9,16–18).
In a pilot feasibility study, we earlier tested the combi-
ation of TUS and thrombolysis in 25 STEMI patients and
chieved TIMI flow grade 3 in 65% of patients at 90-min
ngiography (19). Therefore, we conducted the multicenter,
andomized controlled PLUS (Perfusion by ThromboLytic
nd UltraSound) trial to investigate whether TUS could
mprove the proportion of STEMI patients achieving TIMI
ow grade 3 and50% ST-segment resolution 60 min after
hrombolysis.
ethods
tudy population. The PLUS trial was a randomized,
ouble-blind, active-control trial conducted at 44 centers in
urope, Argentina, Canada, and the U.S. (see Online
ppendix). The study was conducted according to princi-
les of the Declaration of Helsinki and standards of the
nternational Committee on Harmonisation Good Clinical
ractice. The institutional review board at each site ap-
roved the protocol, and all patients provided written
nformed consent before enrollment.
Eligible patients were 18 to 75 years of age, with onset of
TEMI symptoms within 6 h, ST-segment elevation 0.1
V in 2 contiguous electrocardiographic (ECG) leads, and wbility to provide informed consent. Exclusion criteria were
regnancy, cardiogenic shock (systolic BP 90 mm Hg),
ncontrolled hypertension (180/110 mm Hg), left bundle
ranch block or pacemaker ECG rhythm, prior coronary
ypass surgery, percutaneous coronary intervention (PCI)
ithin past 14 days, active internal bleeding or coagulopa-
hy/bleeding diathesis, previous hemorrhagic stroke, or
schemic stroke within past 1 year.
tudy design and randomization. Patients who met eligibility
riteria were randomly assigned in a 1:1 ratio to: 1) thrombol-
sis plus TUS, or 2) control therapy (thrombolysis plus sham
ltrasound transducer/therapy). Randomization was per-
ormed via centralized telephone hotline that assigned
atients to active versus sham transducers with sealed
nvelopes. Trial randomization was stratified by infarct
ocation (anterior vs. other), and randomization blocks of 6
atients were maintained at each site.
tudy interventions. Aspirin (162 to 325 mg at presentation
nd daily) and unfractionated heparin (60 U/kg bolus)  12
/kg/h) or enoxaparin (30 mg IV  1 mg/kg administered
C) were given to all patients.
pen-label thrombolytic ther-
py, either reteplase/retavase or
enecteplase/TNKase, was ad-
inistered in both treatment
roups at full dose according to
he manufacturer’s instruction
or acute STEMI. Within 5 min
f thrombolytic administration,
ltrasound gel and a single-use
ltrasound transducer was ap-
lied to the anterior chest wall as
hown in Figure 1A. The TUS
atients received transcutaneous,
ow-frequency ultrasound therapy via the Timi3 Systems
ltrasound System (Timi3 Systems, Inc., Santa Clara,
alifornia) (Fig. 1B). This device delivered low-frequency
28.3  0.3 kHz) ultrasound at maximum power (23.0 
.4 W) over an effective radiating area of 57.6  5.5 cm2.
coustic output was pulsed for 12-ms duration at a pulse
epetition rate of 25 Hz yielding peak temporal average
ntensity of 0.12 W/cm2 and a spatial peak pulse average
ntensity of 0.38 W/cm.2 Control patients were attached to
he same ultrasound generator plus a sham transducer and
xperienced mild warmth and vibration to the chest wall
ithout therapeutic ultrasound. Ultrasound transmission
as to be delivered for 60  5 min unless worsening
schemia or hemodynamic compromise necessitated earlier
esuscitation or angiography. Coronary angiography was
andated at 60 min after thrombolytic administration, and
ll subsequent revascularization decisions were left to the
nvestigator’s discretion.
tudy end points. Primary end points of the PLUS trial
Abbreviations
and Acronyms
ECG  electrocardiogram
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis In
Myocardial Infarction
TUS  transcutaneous
ultrasoundere the proportion of STEMI patients achieving: 1) TIMI
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354ow grade 3; and 2) 50% cumulative ST-segment reso-
ution 60 min after initial thrombolytic administration.
nly angiograms and ECGs performed between 55 and 79
in after thrombolytic administration and before a PCI
ere included in these primary end point analyses. To be
valuable for the primary end points, the transducer must
ave also been placed within 10 min of thrombolytic bolus
dministration and TUS continued for 40-min duration.
respecified secondary end points included 60-min and
0-min comparisons of combined TIMI flow grades 2 and
, TIMI frame count (20,21), TIMI myocardial perfusion
blush” grade (22,23), quantitative and categorical ST-
egment resolution (24,25), and 30-day composite and
ndividual clinical outcomes. It was anticipated that some
atients would have early or “rescue” PCI after infarct artery
ngiography. Therefore, 90-min (80- to 100-min) angio-
raphic and ECG secondary end point analyses were also
erformed.
ata collection and statistical analysis. Study data were
ollected on standardized case report forms. Coronary
ngiograms were forwarded to the PERFUSE Angio-
raphic Core Laboratory (Boston, Massachusetts) for inde-
Figure 1. Transcutaneous Ultrasound Device
(A) Schematic diagram of transcutaneous ultrasound transducer applied to
patient’s mid-chest. (B) Transcutaneous Ultrasound Generator and
Transducer.endent interpretation blinded to treatment assignment. the ECGs were obtained at baseline and 60, 90, and 180
in after thrombolytic administration and forwarded to the
arvard Clinical Research Institute ECG Core Laboratory
Boston, Massachusetts). The ST-segment resolution was
etermined with the method described by Schroeder et al.
ith percentage ST-segment resolution calculated accord-
ng to formula: ( baseline ST-segment elevation 
ollow-up ST-segment elevation)/ baseline ST-segment
levation (24,25).
Treatment groups were compared for baseline character-
stics with analysis of variance and the Cochran-Mantel-
aenszel test, controlling for infarct location. Statistical
nalysis of the treatment groups for the 2 primary end points
nd all binary angiographic, clinical, or ST-segment reso-
ution outcomes were performed with logistic regression.
ontinuous outcomes were analyzed with analysis of covari-
nce. The TUS was expected to improve the proportion of
atients achieving 60-min TIMI grade 3 flow (60% or more
s. 45%) and 50% ST-segment resolution (55% or more
s. 40%) versus control. Therefore, allowing for 15% rate of
on-evaluable patients, we sought to enroll 560 patients in
he PLUS trial to generate80% power for both end points
ith an overall 2-sided alpha  0.05. The Hochberg
tep-down procedure was planned for assessing overall trial
ignificance. All statistical analyses were performed by
TATPROBE, Inc. (Ann Arbor, Michigan) with SAS
ersion 8.2 (SAS, Cary, North Carolina). The authors had
ull access to the data and take responsibility for integrity of
he data. All authors have read and agree to the manuscript
s written.
An independent Safety and Efficacy Monitoring Com-
ittee collected adverse event reports, monitored patient
afety, and reviewed interim results. Interim analyses were
lanned after angiographic assessment of 150 and 400
atients. After the 150 patient interim analysis, the Safety
nd Efficacy Monitoring Committee requested an updated
eview of all available 60-min angiographic (n  315) and
CG (n 181) data. On the basis of this review, the Safety
nd Efficacy Monitoring Committee recommended discon-
inuation of the PLUS trial in July 2003 because of low
ikelihood of TUS achieving significant differences in TIMI
ow grade or ST-segment resolution.
esults
atient characteristics. Figure 2 depicts the overall flow of
tudy participants in the PLUS trial. As shown, 391 patients
eceived experimental TUS or sham therapy and are ana-
yzed for safety and clinical outcomes. Three hundred sixty
atients met protocol eligibility criteria, began TUS therapy
ithin 10 min of thrombolytic bolus, received TUS for
40-min duration, and had data available for primary or
econdary efficacy end point(s). These patients comprised
he “Efficacy Evaluable” group and were subsequently com-
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355ared for baseline characteristics, angiographic results, and
T-segment resolution. Due to absent data, angiograms/
CGs performed outside the 55- to 79-min evaluation
indow, or PCI performed before angiogram/ECG, 329
atients contributed to primary end point TIMI flow grade
nalysis and 266 patients contributed to the primary end
oint ST-segment resolution analysis.
Table 1 compares, among the 360 “Efficacy Evaluable”
atients, baseline characteristics between the TUS and
ontrol groups. There were no significant differences in age,
ender, comorbidities, symptom duration, thrombolytic
gent, baseline cardiac troponin I concentration, infarct
ocation, or cumulative ST-segment elevation between
reatment groups. Investigators initiated the TUS/control
sham” therapy within 1 min of thrombolytic administration
nd continued the experimental therapy for 58 min in both
reatment groups before infarct artery angiogram. Investi-
ators performed early PCI in nearly three-fourths of
atients in both groups. All 6 cases of clinically emergent
escue PCI occurred in the control group.
ngiographic and ST-segment resolution outcomes.
igures 3 and 4 demonstrate the primary end point results
etween TUS and control groups. There was no significant
N= 396 
Randomized 
(Intended enrollment = 560) 
N=5  Not ITT Evaluable 
Device Not Applied 
N= 391 
Intent-to-Treat
N= 360 
Efficacy Evaluable
N= 329 
Evaluable TIMI Flow 
At 60 min
N= 266 
Evaluable ST Resolution  
at 60 min
Not Efficacy Evaluable 
Protocol Violation (N=16) 
Too much time between lytic and TUS (N=9) 
< 40 minutes of TUS (N=9) 
N=31  Not Evaluable for TIMI Flow at 60 min 
N=94  Not Evaluable for ST Resolution at 60 min 
Angiogram/ ECG out of window, un-interpretable 
ECG, Emergent PCI
Figure 2. Study Population: Flow of Study Participants Depicting Patients
Evaluable for Primary End Points
ECG  electrocardiogram; ITT  intention to treat; TIMI  Thrombolysis In
Myocardial Infarction.ifference in the proportion of patients achieving TIMI flowrade 3 at 60 min (TUS 40.7% vs. control 48.5%, p 0.10).
here was also no significant difference in the proportion of
atients achieving 50% ST-segment resolution at 60 min
TUS 53.2% vs. control 50.0%, p  0.69). Prespecified
econdary ECG analysis at 90 min, including patient results
Table 1. Comparison of Baseline Characteristics Between TUS and
Control Treatment Groups
TUS
(n  178)
Control
(n  182) p Value
Age (yrs) 56.1 9.3 57.8 10.1 0.10
Female (%) 17.4 14.8 0.48
Prior MI (%) 13.6 13.7 0.95
Diabetes (%) 10.2 15.9 0.10
Location of infarct (%) 0.70
Anterior 36.0 37.9
Other 64.0 62.1
Baseline ST-segment elevation
(cumulative, mm)
9.5 7.5 8.8 6.4 0.57
Baseline troponin I (ng/ml) 3.0 11.9 2.9 9.1 0.22
Symptom onset to lysis (min) 179.8 77.3 195.4 77.2 0.07
Lysis to TUS (min) 0.0 2.9 0.1 2.6 0.91
TUS duration (min) 57.5 5.0 58.4 3.2 0.69
Thrombolytic agent 0.60
TNK t-PA (%) 61.8 61.0
Reteplase (%) 37.6 39.0
Infarct artery (%) 0.30
LAD 35.4 37.2
RCA 48.0 48.3
LCx 15.4 11.1
Other 1.1 3.4
Early “rescue” PCI (%) 73.4 71.3 0.59
LAD  left anterior descending coronary artery; LCx  left circumflex coronary artery;
MImyocardial infarction; PCI percutaneous coronary intervention; RCA right coronary
Figure 3. Angiographic Outcomes
Analysis of Thrombolysis In Myocardial Infarction (TIMI) ﬂow grade 60 min
after thrombolytic administration.artery; t-PA tissue-type plasminogen activator; TUS transcutaneous ultrasound.
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356fter PCI, demonstrated that significantly more TUS pa-
ients achieved 50% ST-segment resolution (76.1% vs.
9.3%, p  0.007). Other secondary angiographic and
T-segment resolution end points are shown in Table 2. No
ifferences between treatment groups were present in 60-
in TIMI flow grade, corrected TIMI frame count, TIMI
yocardial perfusion “blush” grade, or 60-min ST-segment
esolution outcomes.
linical outcomes. The PLUS trial was not designed to
ompare clinical outcomes between treatment groups. Nev-
rtheless, the incidence of major clinical and safety out-
omes are presented in Table 3 for the intent-to-treat
opulation. There were no differences in the rates of death,
einfarction, bleeding events, or composite adverse events
etween treatment groups. Only the rate of cutaneous injury
as significantly increased in TUS-treated patients (4.6%
s. 0.5%, relative risk: 9.1, 95% confidence interval: 1.2 to
9.7, p  0.01).
iscussion
ajor ﬁndings. In this first randomized trial of TUS plus
hrombolysis for STEMI, TUS failed to improve infarct
rtery patency (TIMI flow grade), tissue reperfusion (ST-
egment resolution at 60 min), and clinical outcomes
ompared with thrombolytic therapy alone. Most angio-
raphic, ECG, and clinical outcomes showed no beneficial
ffect of TUS therapy, with the exception of improved
0-min ST-segment resolution. The TUS therapy was
ell-tolerated and did not did not impair patient monitor-
ng or delay transit to the catheterization lab. No reported
Figure 4. ST-Segment Resolution Outcomes
Achievement of 50% ST-segment resolution at 60 min (primary end
point) and 90 min (pre-speciﬁed secondary end point). PCI  percutaneous
coronary intervention.oronary artery ruptures or dissections occurred in the TUSreatment group, and only 1 patient in the TUS treatment
roup suffered left ventricular rupture. Amongst all reported
dverse events, only minor cutaneous injury occurred more
requently in the TUS group.
Ninety minutes after thrombolysis administration, there
as a significantly greater proportion of patients achieving
50% ST-segment resolution in the TUS versus control
roup (76% vs. 59%, p  0.012), including a subset of 106
atients without early PCI (84% TUS vs. 61% control, p 
.029). These favorable ST-resolution outcomes should be
nterpreted cautiously, because only 57% of treated patients
ad interpretable baseline plus 90-min ECGs, and because
ost patients had PCI performed before this ECG assess-
ent. Nonetheless, these finding suggest that TUS might
avorably impact myocardial tissue perfusion and benefit
hrombolytic-treated patients with prolonged delays to an-
iography/PCI.
Comparison groups in the PLUS trial were well-matched
or clinical characteristics, and all patients received contem-
orary thrombolytic regimens. The study investigated a
ovel technology; yet, we were able to blind patients and
nvestigators to treatment assignment through centralized
andomization and the use of sham, nonfunctional trans-
ucers. Protocol adherence was excellent, as shown by
pplication of the experimental TUS device within 1 min of
hrombolytic administration and similar duration of TUS
herapy (58 min) in both treatment groups. All angiographic
nd ST-segment resolution determinations were generated
y core laboratories blinded to treatment assignment.
rior TUS studies. During the past 30 years, researchers have
nvestigated various intravascular and external ultrasound
Table 2. Secondary End Points: Comparison of Angiographic and ECG
Results Between TUS and Control Groups
TUS Control p Value
Angiography evaluable, 60 min (n 329) n 162 n 167
TIMI ﬂow grade 3 40.7% 48.5% 0.10
TIMI ﬂow grade 2/3 72.8% 76.0% 0.39
Corrected TIMI frame count 40 38.4% 44.8% 0.23
Myocardial perfusion grade 3 39.4% 34.1% 0.33
Myocardial perfusion grade 2/3 40.6% 35.3% 0.54
ECG evaluable, 60 min (n 266) n 126 n 140
50% ST-segment resolution 53.2% 50.0% 0.69
30% “no” ST-segment resolution 34.9% 35.0% 0.70
30%–70% “partial” ST-segment resolution 29.4% 28.6%
70% “complete” ST-segment resolution 35.7% 36.4%
ECG evaluable, 90 min, expanded efﬁcacy evaluable
patients, (n 221)
n 113 n 108
50% ST-segment resolution 76.1% 59.3% 0.007
30% “no” ST-segment resolution 16.8% 26.9% 0.24
30%–70% “partial” ST-segment resolution 33.6% 25.9%
70% “complete” ST-segment resolution 49.6% 47.2%
ECG electrocardiographic; TUS transcutaneous ultrasound; TIMI Thrombolysis In Myocar-dial Infarction.
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357nergy modalities for the purpose of recanalizing occluded
essels (9). These studies largely show that therapeutic
ltrasound alone has less ability to restore flow to occluded
essels compared with thrombolytic agents but that recan-
lization is facilitated after combined thrombolytic agent
lus intravascular or extraluminal ultrasound. Such research
fforts began with dissolution of thrombus in peripheral
rteries and veins in animal models (11–13) and have
rogressed to TUS application in canine myocardial infarc-
ion (14), human peripheral arteries (25), and even human
schemic stroke (26). Iida et al. (27) have demonstrated that
US dilates human brachial arteries with 4% to 6% in-
reases in artery diameter occurring after 5 min of TUS
xposure. Siegel et al. (14) demonstrated, most pertinent to
ur study, that tissue plasminogen activator TUS improved
0-min TIMI flow grade versus tissue-type plasminogen
ctivator alone (2.4 1.0 vs. 0.9 1.4, p 0.006) in 24 dogs
ith experimental left anterior descending coronary artery
nfarcts. This group additionally showed that low-frequency
ltrasound improves myocardial perfusion and pH in the
resence of fixed coronary artery occlusion (15). Miyamoto et
l. (18) demonstrated in dogs that TUS produced direct
oronary artery vasodilation—yielding 21% increase in epicar-
ial artery cross-sectional area within 5 min of application.
easons for device failure. Adjunctive TUS failed to im-
rove 60-min TIMI flow grade or ST-segment resolution in
ur study population, contrary to these preclinical results.
ow-frequency ultrasound generators and chest wall trans-
ucers have capably delivered nonionizing mechanical en-
Table 3. Secondary End Points: Comparison of Adver
Death
Reinfarction
Death or reinfarction
Cardiogenic shock
Recurrent ischemia
Stroke
Cardiac rupture/tamponade
Coronary dissection
Major bleeding
Minor bleeding
Cutaneous injury
Erythema
Pain
Bulla/epidermis disruption
Other (not speciﬁed)
Composite events/efﬁcacy (death, reinfarction, cardiogenic
shock, recurrent ischemia)
Composite events/efﬁcacy and safety (death, reinfarction, st
major bleed, recurrent ischemia, rupture, tamponade)
CI confidence interval; RR relative risk; other abbreviations as in Trgy to occluded coronary arteries in prior animal models. she exact mechanism responsible for the effect of ultra-
ound on thrombus dissolution, however, is not completely
nown; and proposed mechanisms for clot dissolution
nclude acoustic cavitation, microstreaming, direct mechan-
cal or thermal effect, and increased clot permeability to
irculating thrombolytic agents (16–18). Prior experiments
f TUS in canine acute thrombotic coronary occlusion
nvolved animals weighing approximately 20 kg, whereas
LUS trial human subjects weighed approximately 80 kg.
hus, we speculate that coronary thrombolysis was not
ugmented in the PLUS trial, because our experimental
US device failed to deliver adequate ultrasound energy
hrough the larger mass of the human chest wall to the
ntracoronary thrombus. The U.S. Food and Drug Admin-
stration and the International Electrotechnical Commis-
ion (IEC) have not issued specific maximal power or
ntensity limits for human therapeutic ultrasound. The
urrently used device has spatial peak temporal average
ntensity and spatial peak pulse average effective intensity
hat easily comply with proposed IEC diagnostic ultrasound
imits of 3 W/cm2 and 24 W/cm2, respectively. It is
nknown whether a different ultrasound frequency, pulse
uration and cycle length, or power settings would have
ielded different results. Increased TUS power or intensity
ight, however, lead to unacceptable rates of skin thermal
njury; thus additional work is needed to develop improved
ltrasound technology, skin cooling measures, or adjunctive
harmacological treatments.
Our negative results are likely not related to trial design,
nical Outcomes Between TUS and Control Group
TUS
(n  195)
Control
(n  196)
RR
(95% CI) p Value
4.1% (8) 3.1% (6) 1.34 (0.47–3.8) 0.58
1.0% (2) 2.0% (4) 0.50 (0.09–2.7) 0.24
5.1% (10) 4.6% (9) 1.12 (0.46–2.7) 0.81
2.1% (4) 3.6% (7) 0.57 (0.17–1.9) 0.36
2.6% (5) 3.6% (7) 0.72 (0.23–2.3) 0.56
0.5% (1) 0.5% (1) 1.01 (0.06–16.0) 0.99
0.5% (1) 0.0% (0) — 0.50
0% (0) 1.0% (2) — 0.25
4.1% (8) 4.1% (8) 1.01 (0.39–2.6) 0.99
9.7% (19) 9.7% (19) 1.01 (0.55–1.8) 0.99
4.6% (9) 0.5% (1) 9.05 (1.2–70.7) 0.01
4 1 —
3 0 —
2 0 —
1 0 —
7.7% (15) 7.7% (15) 1.01 (0.51–2.0) 0.99
9.7% (19) 10.2% (20) 0.95 (0.53–1.7) 0.88se Cli
roke,tatistical analysis, or end point selection issues. As stated in
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358he preceding text, investigators adhered to the protocol
losely and enrolled patients with representative STEMI
linical, ECG, and angiographic features. Primary end point
ubgroup analyses showed no significant treatment benefit
n patient subgroups with left anterior descending coronary
rtery infarcts or non–left anterior descending coronary
rtery infarcts, patients receiving reteplase, patients receiv-
ng tenecteplase, or in patients with symptom duration 2 h
ersus 2 to 4 h versus 4 h. The 60 minute TIMI flow grade
s an accepted measure to compare thrombolytic regimens in
hase II trials (28,29). Strong data also link attainment of 50%
T-segment resolution at 60-min with post-STEMI mortality
30–33). Anticipated rates of 50% ST-segment resolution
nd TIMI flow grade 3 in the control group closely matched
istorical outcomes and pre-study estimates. Angiographic
atency and ST-segment resolution at 90 min after throm-
olysis are more widely validated STEMI trial end points. Yet,
e selected 60-min TIMI flow grade and ST-segment reso-
ution, because we did not want early PCI procedures to impact
rimary end point results or be delayed in critically ill patients.
hether our positive 90-min ST-segment resolution results
ignify a type I statistical error or rather a late enhanced
hrombolysis effect is uncertain.
onclusions
n the first randomized trial of adjunctive TUS and throm-
olysis in patients with STEMI, we showed no enhanced
nfarct artery patency or ST-segment resolution with TUS
0 min after thrombolytic administration. These negative
esults should stimulate TUS investigation in STEMI
atients treated exclusively with thrombolytics and should
ncourage additional bioengineering research, device mod-
fications, or combined TUS use with microbubbles/
harmacologic contrast agents (34) in the future.
eprint requests and correspondence: Dr. Michael Hudson,
enry Ford Hospital (K-14), 2799 West Grand Boulevard,
etroit, Michigan 48202. E-mail: mhudson1@hfhs.org.
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APPENDIX
or a list of the participants in the PLUS trial, please see the online version
f this article.
